Maximilian Franz Schmidt

Maximilian Franz Schmidt

Auto-generated profile, based on publicly available information

Maximilian Franz Schmidt

Department of Chemistry and Pharmacy Medicinal Chemistry Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) Nikolaus-Fiebiger-Straße 10 91058 Erlangen Germany

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2022 in Science
Verified
Journal Article
Closed access
EFElissa A. Fink
Elissa A. Fink
JXJun Xu
Jun Xu
HHHarald Hübner
Harald Hübner
JBJoao M. Braz
Joao M. Braz
PSPhilipp Seemann
Philipp Seemann
PGPeter Gmeiner
Peter Gmeiner
Because nonopioid analgesics are much sought after, we computationally docked more than 301 million virtual molecules against a validated pain target, the α 2A -adrenergic receptor (α 2A AR), seeking new α 2A AR agonists chemotypes that lack the sedation conferred by known α 2A AR drugs, such as dexmedetomidine. We identified 17 ligands with potencies as low as 12 nanomolar, many with partial agonism and preferential G i and G o signaling. Experimental structures of α 2A AR complexed with two of these agonists confirmed the docking predictions and templated further optimization. Several compounds, including the initial docking hit ‘9087 [mean effective concentration (EC 50 ) of 52 nanomolar] and two analogs, ‘7075 and PS75 (EC 50 4.1 and 4.8 nanomolar), exerted on-target analgesic activity in multiple in vivo pain models without sedation. These newly discovered agonists are interesting as therapeutic leads that lack the liabilities of opioids and the sedation of dexmedetomidine.

27 January 2022 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
PDF file
MHMax Erhard Huber
Max Erhard Huber
LTLara Toy
Lara Toy
MSMaximilian Franz Schmidt
Maximilian Franz Schmidt
HVHannah Vogt
Hannah Vogt
JBJulian Budzinski
Julian Budzinski
MSMatthias Schiedel
Matthias Schiedel
A conserved intracellular allosteric binding site (IABS) has recently been identified at several G protein‐coupled receptors (GPCRs). Starting from vercirnon, an intracellular C−C chemokine receptor type 9 (CCR9) antagonist and previous phase III clinical candidate for the treatment of Crohn's disease, we developed a chemical biology toolbox targeting the IABS of CCR9. We first synthesized a fluorescent ligand enabling equilibrium and kinetic binding studies via NanoBRET as well as fluorescence microscopy. Applying this molecular tool in a membrane‐based setup and in living cells, we discovered a 4‐aminopyrimidine analogue as a new intracellular CCR9 antagonist with improved affinity. To chemically induce CCR9 degradation, we then developed the first PROTAC targeting the IABS of GPCRs. In a proof‐of‐principle study, we succeeded in showing that our CCR9‐PROTAC is able to reduce CCR9 levels, thereby offering an unprecedented approach to modulate GPCR activity.

21 March 2025 in Science Advances
Verified
Journal Article
Open access
MCMarina Casiraghi
Marina Casiraghi
HWHaoqing Wang
Haoqing Wang
PBPatrick C. Brennan
Patrick C. Brennan
CHChris Habrian
Chris Habrian
HHHarald Hübner
Harald Hübner
BKBrian K. Kobilka
Brian K. Kobilka
G protein–coupled receptors (GPCRs) exhibit varying degrees of selectivity for different G protein isoforms. Despite the abundant structures of GPCR–G protein complexes, little is known about the mechanism of G protein coupling specificity. The β 2 -adrenergic receptor is an example of GPCR with high selectivity for Gαs, the stimulatory G protein for adenylyl cyclase, and much weaker for the Gαi family of G proteins inhibiting adenylyl cyclase. By developing a Gαi-biased agonist (LM189), we provide structural and biophysical evidence supporting that distinct conformations at ICL2 and TM6 are required for coupling of the different G protein subtypes Gαs and Gαi. These results deepen our understanding of G protein specificity and bias and can accelerate the design of ligands that select for preferred signaling pathways.

2 May 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
GCGeng Chen
Geng Chen
JXJun Xu
Jun Xu
AIAsuka Inoue
Asuka Inoue
MSMaximilian F. Schmidt
Maximilian F. Schmidt
CBChen Bai
Chen Bai
YDYang Du
Yang Du
GPR88 is an orphan class A G-protein-coupled receptor that is highly expressed in the striatum and regulates diverse brain and behavioral functions. Here we present cryo-EM structures of the human GPR88-Gi1 signaling complex with or without a synthetic agonist(1R, 2R)-2-PCCA. We show that(1R, 2R)-2-PCCA is an allosteric modulator binding to a herein identified pocket formed by the cytoplasmic ends of transmembrane segments 5, 6, and the extreme C terminus of the α5 helix of Gi1. We also identify an electron density in the extracellular orthosteric site that may represent a putative endogenous ligand of GPR88. These structures, together with mutagenesis studies and an inactive state model obtained from metadynamics simulations, reveal a unique activation mechanism for GPR88 with a set of distinctive structure features and a water-mediated polar network. Overall, our results provide a structural framework for understanding the ligand binding, activation and signaling mechanism of GPR88, and will facilitate the innovative drug discovery for neuropsychiatric disorders and for deorphanization of this receptor.

15 July 2022 in ACS Chemical Biology
Verified
Journal Article
Closed access
LTLara Toy
Lara Toy
MHMax E. Huber
Max E. Huber
MSMaximilian F. Schmidt
Maximilian F. Schmidt
DWDorothee Weikert
Dorothee Weikert
MSMatthias Schiedel
Matthias Schiedel

8 November 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
AKAdam Konieczny
Adam Konieczny
MCMarcus Conrad
Marcus Conrad
FEFabian J. Ertl
Fabian J. Ertl
JGJakob Gleixner
Jakob Gleixner
AGAlbert O. Gattor
Albert O. Gattor
MKMax Keller
Max Keller